• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News

Our short URL is biophar.ma

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Infections

olorofim
Posted inClinical Trials, Infections, Rare/Orphan Diseases

Olorofim: New Antifungal Drug

June 9, 2022June 9, 2022

Olorophim by F2G and Shionogi & Co. is focused on invasive aspergillosis treatment.

Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus
Posted inCOVID-19, Infections, New Drugs, Regulatory

Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus

June 8, 2022June 8, 2022

One dose of AstraZeneca’s monoclonal antibody cocktail protects against COVID-19 for six months or longer.

Covifenz: Medicago’s Plant-Derived COVID-19 Vaccine
Posted inCOVID-19, Infections, New Drugs, Regulatory

Covifenz: Medicago’s Plant-Derived COVID-19 Vaccine

June 5, 2022June 5, 2022

Innovative Medicago’s vaccine is made by molecular pharming technology.

Talicia: Highly Effective Eradication Regimen for Helicobacter pylori
Posted inInfections, New Drugs, Oncology, Regulatory

Talicia: Highly Effective Eradication Regimen for Helicobacter pylori

June 5, 2022June 10, 2022

Combination drug invented by RedHill Biopharma will get rid of Helicobacter pylori infection in 90% of patients.

Monkeypox 2022. Full Review
Posted inInfections, Research

Monkeypox 2022. Full Review

June 1, 2022June 14, 2022

Monkeypox as a new threat to humanity.

Posts navigation

1 2 3 … 9 Older posts
BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2022 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News